WPW 증후군 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 진단별, 치료별, 최종 사용자별, 지역별 및 경쟁(2021-2031년)

The Global Wolff Parkinson White syndrome Market is projected to expand from USD 1.62 Billion in 2025 to USD 2.28 Billion by 2031, registering a CAGR of 5.86%. Wolff-Parkinson-White (WPW) syndrome, a congenital heart defect featuring an extra electrical pathway that bypasses the normal conduction system to cause tachycardia, is seeing increased market activity driven by better diagnosis of complex arrhythmias and progress in electrophysiology, particularly catheter ablation. There is a marked clinical shift towards curative, minimally invasive procedures rather than lifelong medication, which fuels the demand for specialized ablation catheters and 3D mapping systems, independent of broader healthcare digitalization trends.

However, market growth faces obstacles related to managing asymptomatic patients and the intricacies of risk stratification. The challenge lies in accurately predicting sudden cardiac events in patients lacking obvious symptoms, which complicates treatment decisions. Highlighting this dilemma, the Heart Rhythm Society reported in 2024 that life-threatening events in pediatric WPW patients occur at a rate of 0.8 to 1.9 per 1,000 person-years. This statistic emphasizes the difficult balance healthcare providers must strike between the risks of intervention and the possibility of severe adverse outcomes.

Market Driver

The Global Wolff-Parkinson-White Syndrome Market is being transformed by the rising use of catheter ablation, marking a shift from chronic drug therapy to curative treatments. This transition is hastened by the launch of technologies like Pulsed Field Ablation (PFA), which improves safety and speed, thereby boosting patient volume in electrophysiology labs. This demand is evident in financial results; Medtronic's 'Fourth Quarter Fiscal Year 2025 Financial Results' from May 2025 showed a nearly 30% revenue jump in their Cardiac Ablation Solutions business, driven by the uptake of their advanced portfolio, confirming ablation's status as a primary therapy for accessory pathway tachycardias.

Alongside ablation, progress in electrophysiological diagnostic mapping is vital for accurately locating accessory pathways to ensure successful outcomes. Modern 3D mapping systems now employ high-density electrode catheters for real-time, detailed maps, which lowers fluoroscopy reliance and re-ablation rates. Johnson & Johnson's 'Second Quarter 2025 Earnings Release' in July 2025 reported an 11% sales increase in their electrophysiology division, attributed to the demand for these advanced systems. This infrastructure is further supported by the equipment needs of broader conditions like atrial fibrillation, which the Heart Rhythm Society noted in 2025 affects roughly 37.5 million people globally, thereby reinforcing the resources available for WPW care.

Market Challenge

A major hurdle to market progression is the difficulty of risk stratification and managing asymptomatic individuals. When patients exhibit the Wolff-Parkinson-White pattern without symptoms, clinicians often choose conservative monitoring over immediate procedures. This approach limits the number of elective catheter ablations, subsequently lowering the demand for therapeutic devices and diagnostic mapping tools. The uncertainty surrounding which asymptomatic patients might eventually suffer life-threatening arrhythmias leads to lower procedural adoption rates.

This cautious clinical environment constrains revenue potential for device makers. In 2024, the American Heart Association stated that about 65 percent of newly diagnosed ventricular pre-excitation cases were asymptomatic and did not require immediate invasive action. This significant volume of patients ineligible for immediate correction imposes a natural limit on market expansion. Consequently, the preference for long-term observation rather than curative ablation for this substantial patient group maintains a more moderate growth rate for the global market.

Market Trends

Artificial Intelligence (AI) is transforming electrophysiological mapping by automating the interpretation of intracardiac signals to precisely locate accessory pathways in Wolff-Parkinson-White syndrome. These AI algorithms improve accuracy, shorten procedure times, and reduce operator error. A report by Industry Today in December 2025 noted that by May 2025, the U.S. led global adoption, with nearly 60 percent of top hospitals employing AI-enabled mapping systems, signaling a strong shift toward intelligent diagnostics that improve safety for complex anatomies.

Concurrently, Robotic Magnetic Navigation (RMN) is overcoming the constraints of manual catheter manipulation in difficult anatomical regions. RMN systems offer enhanced stability, allowing for precise ablation without the fatigue linked to manual methods. Stereotaxis highlighted this progress in July 2025 by announcing FDA 510(k) clearance for the MAGiC Sweep Catheter, a robotically navigated high-density mapping catheter with 20 electrodes designed to improve precision. These innovations are crucial for reducing recurrence rates in complex cases where traditional manual approaches often fall short.

Key Market Players

• Medtronic Plc
• Abbott Laboratories Corporation
• Boston Scientific Corporation
• St. Jude Medical LLC
• GlaxoSmithKline LLC
• Teva Pharmaceutical Industries Ltd
• Sanofi S.A
• Novartis International AG
• Angio Dynamics Inc
• Meril Life Sciences Pvt. Ltd

Report Scope

In this report, the Global Wolff Parkinson white syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Wolff Parkinson white syndrome Market, By Type

• Type A
• Type B

Wolff Parkinson white syndrome Market, By Diagnosis

• Electrocardiogram (ECG)
• Electrophysiological Testing
• Other Diagnosis

Wolff Parkinson white syndrome Market, By Treatment

• Drugs
• Cardioversion
• Radiofrequency Catheter Ablation
• Surgery
• Artificial Pacemaker
• Other Treatments

Wolff Parkinson white syndrome Market, By End User

• Hospitals And Clinics
• Academic and Research Institutes
• Others

Wolff Parkinson white syndrome Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Wolff Parkinson white syndrome Market.

Available Customizations:

Global Wolff Parkinson white syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Wolff Parkinson white syndrome Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Type A, Type B)
  • 5.2.2. By Diagnosis (Electrocardiogram (ECG), Electrophysiological Testing, Other Diagnosis)
  • 5.2.3. By Treatment (Drugs, Cardioversion, Radiofrequency Catheter Ablation, Surgery, Artificial Pacemaker, Other Treatments)
  • 5.2.4. By End User (Hospitals And Clinics, Academic and Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Wolff Parkinson white syndrome Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Diagnosis
  • 6.2.3. By Treatment
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Wolff Parkinson white syndrome Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Diagnosis
      • 6.3.1.2.3. By Treatment
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Wolff Parkinson white syndrome Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Diagnosis
      • 6.3.2.2.3. By Treatment
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Wolff Parkinson white syndrome Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Diagnosis
      • 6.3.3.2.3. By Treatment
      • 6.3.3.2.4. By End User

7. Europe Wolff Parkinson white syndrome Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Diagnosis
  • 7.2.3. By Treatment
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Wolff Parkinson white syndrome Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By Treatment
      • 7.3.1.2.4. By End User
  • 7.3.2. France Wolff Parkinson white syndrome Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By Treatment
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Wolff Parkinson white syndrome Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By Treatment
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Wolff Parkinson white syndrome Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Diagnosis
      • 7.3.4.2.3. By Treatment
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Wolff Parkinson white syndrome Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Diagnosis
      • 7.3.5.2.3. By Treatment
      • 7.3.5.2.4. By End User

8. Asia Pacific Wolff Parkinson white syndrome Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Diagnosis
  • 8.2.3. By Treatment
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Wolff Parkinson white syndrome Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By Treatment
      • 8.3.1.2.4. By End User
  • 8.3.2. India Wolff Parkinson white syndrome Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By Treatment
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Wolff Parkinson white syndrome Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By Treatment
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Wolff Parkinson white syndrome Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Diagnosis
      • 8.3.4.2.3. By Treatment
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Wolff Parkinson white syndrome Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Diagnosis
      • 8.3.5.2.3. By Treatment
      • 8.3.5.2.4. By End User

9. Middle East & Africa Wolff Parkinson white syndrome Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Diagnosis
  • 9.2.3. By Treatment
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Wolff Parkinson white syndrome Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By Treatment
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Wolff Parkinson white syndrome Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By Treatment
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Wolff Parkinson white syndrome Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By Treatment
      • 9.3.3.2.4. By End User

10. South America Wolff Parkinson white syndrome Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Diagnosis
  • 10.2.3. By Treatment
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Wolff Parkinson white syndrome Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Diagnosis
      • 10.3.1.2.3. By Treatment
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Wolff Parkinson white syndrome Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Diagnosis
      • 10.3.2.2.3. By Treatment
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Wolff Parkinson white syndrome Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Diagnosis
      • 10.3.3.2.3. By Treatment
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Wolff Parkinson white syndrome Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Medtronic Plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Corporation
• 15.3. Boston Scientific Corporation
• 15.4. St. Jude Medical LLC
• 15.5. GlaxoSmithKline LLC
• 15.6. Teva Pharmaceutical Industries Ltd
• 15.7. Sanofi S.A
• 15.8. Novartis International AG
• 15.9. Angio Dynamics Inc
• 15.10. Meril Life Sciences Pvt. Ltd

16. Strategic Recommendations

17. About Us & Disclaimer